0QLQ.L - Ypsomed Holding AG
Ypsomed Holding AG
Brunnmattstrasse 6
Burgdorf 3401
Switzerland
41 34 424 41 11
https://www.ypsomed.com
Settore/i:
Settore:
Impiegati a tempo pieno: 2.059
Figure dirigenziali chiave
| Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
|---|---|---|---|---|
| Mr. Simon Michel | CEO & Member of the Board | 1,14M | N/D | 1977 |
| Mr. Niklaus Ramseier | Chief Financial Officer | N/D | N/D | 1963 |
| Mr. Frank Mengis | Chief Operating Officer | N/D | N/D | 1964 |
| Thomas Kutt | Head of Investor Relations | N/D | N/D | N/D |
| Dr. Nicolas Meyer | Chief Legal Officer | N/D | N/D | 1971 |
| Mr. Michael Zaugg | Chief Corp. Officer | N/D | N/D | 1972 |
| Ms. Ulrike Bauer | Chief Bus. Officer of Ypsomed Delivery Systems | N/D | N/D | 1969 |
| Mr. Sebastien Delarive | Chief Bus. Officer of Ypsomed Diabetes Care | N/D | N/D | 1969 |
Descrizione
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Governance aziendale
L'ISS Governance QualityScore di Ypsomed Holding AG al 1 maggio 2023 è 6. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 6; diritti degli azionisti: 6; retribuzione: 6.
